These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 21103975)

  • 21. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
    Kim M; Turnquist H; Jackson J; Sgagias M; Yan Y; Gong M; Dean M; Sharp JG; Cowan K
    Clin Cancer Res; 2002 Jan; 8(1):22-8. PubMed ID: 11801536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk.
    Jonker JW; Merino G; Musters S; van Herwaarden AE; Bolscher E; Wagenaar E; Mesman E; Dale TC; Schinkel AH
    Nat Med; 2005 Feb; 11(2):127-9. PubMed ID: 15685169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).
    Elkind NB; Szentpétery Z; Apáti A; Ozvegy-Laczka C; Várady G; Ujhelly O; Szabó K; Homolya L; Váradi A; Buday L; Kéri G; Német K; Sarkadi B
    Cancer Res; 2005 Mar; 65(5):1770-7. PubMed ID: 15753373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BCRP/ABCG2 inhibitors: a patent review (2009-present).
    Wiese M
    Expert Opin Ther Pat; 2015; 25(11):1229-37. PubMed ID: 26291461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
    Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
    Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of breast cancer resistance protein on cancer treatment outcomes.
    Ross DD; Nakanishi T
    Methods Mol Biol; 2010; 596():251-90. PubMed ID: 19949928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
    Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
    Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2).
    Szafraniec MJ; Szczygieł M; Urbanska K; Fiedor L
    Drug Metab Rev; 2014 Nov; 46(4):459-74. PubMed ID: 25036722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.
    Nakanishi T; Ross DD
    Chin J Cancer; 2012 Feb; 31(2):73-99. PubMed ID: 22098950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2).
    Matsson P; Englund G; Ahlin G; Bergström CA; Norinder U; Artursson P
    J Pharmacol Exp Ther; 2007 Oct; 323(1):19-30. PubMed ID: 17616561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human ABC transporter ABCG2 in cancer chemotherapy: drug molecular design to circumvent multidrug resistance.
    Ishikawa T; Saito H; Hirano H; Inoue Y; Ikegami Y
    Methods Mol Biol; 2012; 910():267-78. PubMed ID: 22821599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2).
    Gradhand U; Kim RB
    Drug Metab Rev; 2008; 40(2):317-54. PubMed ID: 18464048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dietary polyacetylenes of the falcarinol type are inhibitors of breast cancer resistance protein (BCRP/ABCG2).
    Tan KW; Killeen DP; Li Y; Paxton JW; Birch NP; Scheepens A
    Eur J Pharmacol; 2014 Jan; 723():346-52. PubMed ID: 24269959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.
    Hasanabady MH; Kalalinia F
    J Biosci; 2016 Jun; 41(2):313-24. PubMed ID: 27240991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A; Wiese M
    ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense.
    Leslie EM; Deeley RG; Cole SP
    Toxicol Appl Pharmacol; 2005 May; 204(3):216-37. PubMed ID: 15845415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
    Imai Y; Tsukahara S; Asada S; Sugimoto Y
    Cancer Res; 2004 Jun; 64(12):4346-52. PubMed ID: 15205350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.